American Water Works Company, Inc. 8-K

What Happened

• American Water Works Company, Inc. (AWK) disclosed on June 9, 2026 that two wholly owned subsidiaries filed settlement agreements in their general rate cases. California‑American Water Company (Cal Am) filed a partial settlement with the CPUC on June 8, 2026; Virginia American Water filed a “black box” stipulation with the VSCC on June 5, 2026.
• Under the Cal Am partial settlement, Cal Am would receive incremental annualized water and wastewater revenue of $24 million for the 2027 test year, $21 million for the 2028 escalation year, and $22 million for the 2029 attrition year (AWK had proposed $43M / $22M / $26M for those years). If construction work in progress (CWIP) is excluded from rate base, the 2027 and 2028 amounts would drop to about $20M and $19M, respectively. New rates would take effect January 1, 2027 upon final CPUC action.
• Under the Virginia American Water stipulation, the parties agreed to a $16 million annualized revenue increase driven mainly by roughly $115 million of capital investments (May 2025–April 2027). The stipulation also sets a return on equity (ROE) of 9.75% and an equity ratio of 51.79% for specified future filings (prior case used 9.70% ROE and 45.67% equity). Interim rates became effective May 2, 2026; the stipulation is subject to VSCC approval.

Key Details

• Cal Am incremental annualized revenues per settlement: $24M (2027), $21M (2028), $22M (2029).
• AWK’s revised proposed position for Cal Am: $43M (2027), ~$22M (2028), ~$26M (2029).
• Virginia American Water agreed annualized increase: $16M; ROE agreed at 9.75% and equity component 51.79%.
• Capital investments driving these requests: ~ $750M for Cal Am (2025–2028) and ~ $115M for Virginia American Water (May 2025–Apr 2027).

Why It Matters

• These settlements, if approved, would raise regulated revenues for AWK subsidiaries and support recovery of recent and planned capital investments, which can affect cash flow and rate base growth for the company.
• Outcomes remain subject to final regulatory approval and unresolved issues (notably CWIP treatment in Cal Am’s case) that could reduce the approved revenue increases. Investors should note the company’s caution that final decisions, timing, and other regulatory risks could change expected benefits.